IMR Press / RCM / Volume 2 / Issue S1 / pii/1561516078088-1718305247

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Pathophysiology of Radiocontrast Nephropathy and Use of Fenoldopam for Its Prevention
Show Less
1 Departments of Nephrology and Transplantation, University of California, San Francisco, CA MathurConsulting
Rev. Cardiovasc. Med. 2001, 2(S1), 4–8;
Published: 20 January 2001
There are no proven therapeutic agents for the prevention or treatment of acute renal failure. Radiocontrast agents induce intense vasoconstriction in the renal medulla, which is hypoxic even in normal physiologic states, thereby aggravating the imbalance of medullary oxygen supply and demand. Fenoldopam specifically increases blood flow to the renal medulla through selective agonism of dopamine-1 receptors and has been found to prevent radiocontrast nephropathy in several investigations, including one randomized, double-blind, placebo-controlled trial.
Radiocontrast nephropathy
Acute renal failure
Acute tubular necrosis
Back to top